A Controlled Pregabalin Trial In Fibromyalgia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00230776|
Recruitment Status : Completed
First Posted : October 3, 2005
Last Update Posted : October 10, 2012
|Condition or disease||Intervention/treatment||Phase|
|Fibromyalgia||Drug: pregabalin Drug: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||740 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia|
|Study Start Date :||October 2005|
|Study Completion Date :||July 2006|
- To evaluate the efficacy of pregabalin for pain relief by comparing the mean pain score between treatment groups and placebo.
- To evaluate the efficacy of pregabalin for improvement in sleep, fatigue, health-related quality of life, functioning and mood disturbance associated with fibromyalgia. To evaluate safety and tolerability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230776
Show 91 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|